rais pt
updat model otezla
updat model better reflect updat guidanc adjust
otezla sale tweak biosimilar outer year model
chang posit impact dcf increas pt
tr target
figur million dollar except per share data
strh research compani report updat
page
incom product includ product contract/royalti oper oper itemsnet interest incom incom exc spec provis rate net ep per dilut s/o use adjust inc
inc biotechnolog compani engag discoveri develop
manufactur market human therapeut product includ follow brand aranesp
parsabiv prolia repatha sensipar vectibix xgeva compani found william
bow jr franklin pitcher johnson jr georg rathmann joseph rubinfeld april
headquart thousand oak ca
tough tape ahead elect believ provid predict earn
histori beat estim quarterli specialti drive growth product mid-way
life cycl see stabil growth potenti upsid product includ biosimilar
aimovig even otezla repatha think street underestim abil grow
new product biosimilar come market non-legaci product grow believ
street need pipelin success true growth see upsid await signific late-
stage data readout tezepleumab see earli pipelin data readout
rate share buy
valuat risk
target price deriv dcf assum legaci sale declin
non-legaci peak sale adjust pipelin sale
use discount rate appropri lower risk biotech use higher termin valu vs
model beyond patent cliff believ use capit product
risk rate price target includ on-going generic/biosimilar competit part price
pressur poorer expect sale pipelin failur
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
